IBS, the Microbiome and the Potential of Probiotics:
FDA authorizes IND to study the effects of DS-01 (Daily Synbiotic) on patients living with IBS

Cramping. Abdominal pain. Bloating, gas, and diarrhea. These are unpleasant words to read and even more troublesome to endure physically. But that’s the day-to-day experience of those who suffer from irritable bowel syndrome, or IBS, the most common gastrointestinal condition worldwide. IBS affects an estimated 10-15% of the U.S. population and nearly 12% of all … Continue reading IBS, the Microbiome and the Potential of Probiotics:
FDA authorizes IND to study the effects of DS-01 (Daily Synbiotic) on patients living with IBS